Of the approximately 73 million induced abortions that took place between 2015 and 2019, an estimated 24 million were unsafe. In line with current scientific data and the World Health Organization’s recommendations, Linepharma International aims to make safe abortion and sexual and reproductive healthcare accessible to as many people as possible, in as many places as possible, regardless of their social, political, or economic circumstances.

Primarily through partnerships with local distribution partners, we have commercialized mifepristone in over 25 countries worldwide. Initially a Euro-centric commercial focus, we now focus on expanding access to safe medication abortion and sexual and reproductive healthcare services and tools to the broader international market.

Linepharma has successfully introduced mifepristone and misoprostol products for medication abortion in various countries throughout Asia and Latin America in partnership with local distributors while establishing full-scale pharmaceutical operations teams in key markets in Canada and Japan.

Linepharma International is headquartered in the United Kingdom and operates affiliate offices in Toronto, Canada, and Tokyo, Japan.